Skip to main content

Drug Interactions between Aminatal Plus One and maralixibat

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

multivitamin, prenatal maralixibat

Applies to: Aminatal Plus One (multivitamin, prenatal) and maralixibat

MONITOR: Maralixibat may affect the absorption of fat-soluble vitamins (FSV) including A, D, E, and K. In a clinical study, emergent FSV deficiency was reported in 10% of patients during 48 weeks of treatment. In addition, it should be noted that patients with Alagille syndrome (ALGS) can have FSV deficiency at baseline.

MANAGEMENT: Clinical and laboratory monitoring of serum FSV levels is recommended at baseline and during treatment with maralixibat. If FSV deficiency is diagnosed, supplementation with FSV should be initiated. If FSV deficiency persists or worsens despite adequate FSV supplementation, discontinuation of maralixibat should be considered.

References

  1. (2021) "Product Information. Livmarli (maralixibat)." Mirum Pharmaceuticals, Inc.

Switch to consumer interaction data

Drug and food interactions

Moderate

multivitamin, prenatal food

Applies to: Aminatal Plus One (multivitamin, prenatal)

ADJUST DOSING INTERVAL: Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa.

Food taken in conjunction with oral iron supplements may reduce the bioavailability of the iron. However, in many patients intolerable gastrointestinal side effects occur necessitating administration with food.

MANAGEMENT: Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.

References

  1. "Product Information. Feosol (ferrous sulfate)." SmithKline Beecham
  2. (2021) "Product Information. Accrufer (ferric maltol)." Shield Therapeutics

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer